Competitor Analysis: Anti-Infective Peptides, New Report Launched

The present Competitive Intelligence Report about Anti-Infective Peptides used to treat bacterial, viral and fungal infections provides a competitor evaluation in the field of R&D projects with anti-infective peptides as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Anti-Bacterial Peptides

Anti-bacterial peptides are used to treat infectious diseases such as complicated skin and skin structure infections (cSSSI), gram-positive and gram-negative infections, prevention of catheter-related infections, otitis media, gingivitis and many more.

Anti-Fungal Peptides

Anti-fungal peptides are used to treat infections such as oesophageal candidiasis, aspergillosis, oral candida infections, vaginal yeast infections and many more.

Anti-Viral Peptides

Anti-viral peptides are used to treat infections such as HIV and AIDS, influenza incl. H5N1 strains, hepatitis C virus infections (HCV).

The report includes a compilation of current active projects in research and development of anti-infective peptides. In addition, the report lists company-specific R&D pipelines of anti-infective peptides.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 68 pages “Competitor Analysis: Anti-Infective Peptides” report covering 2013 Sales of Major Anti-Infective Peptides, Anti-Bacterial Peptides, Anti-Fungal Peptides, Anti-Viral Peptides, Corporate Anti-Infective Peptide R&D Pipelines.

Know more about this report at – http://mrr.cm/Zjj

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare